LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Home・Aandelen Lijst・Pulmatrix Inc

Pulmatrix Inc

Gesloten

4.26 -3.4

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.26

Max

4.41

Belangrijke statistieken
By Trading Economics
Inkomsten	672K -877K
EPS	-0.24
Winstmarge	-60,266.667
Werknemers	2
EBITDA	671K -877K

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-1.2M 17M
Vorige openingsprijs	7.66
Vorige sluitingsprijs	4.26

Pulmatrix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 dec 2025, 23:21 UTC

Winsten

Acquisities, Fusies, Overnames

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dec 2025, 23:14 UTC

Acquisities, Fusies, Overnames

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dec 2025, 22:01 UTC

Belangrijke Marktbewegers

Costco Wholesale Reports Higher Monthly Sales

3 dec 2025, 21:38 UTC

Winsten

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dec 2025, 23:59 UTC

Marktinformatie

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dec 2025, 23:49 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dec 2025, 23:13 UTC

Marktinformatie

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dec 2025, 23:10 UTC

Winsten

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dec 2025, 23:08 UTC

Marktinformatie

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dec 2025, 23:06 UTC

Acquisities, Fusies, Overnames

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dec 2025, 22:59 UTC

Acquisities, Fusies, Overnames

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dec 2025, 22:45 UTC

Marktinformatie

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dec 2025, 22:20 UTC

Winsten

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dec 2025, 22:19 UTC

Winsten

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dec 2025, 22:17 UTC

Winsten

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dec 2025, 22:16 UTC

Winsten

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dec 2025, 22:15 UTC

Winsten

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dec 2025, 22:10 UTC

Acquisities, Fusies, Overnames

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dec 2025, 22:09 UTC

Acquisities, Fusies, Overnames

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

3 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

3 dec 2025, 21:49 UTC

Winsten

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:23 UTC

Winsten

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dec 2025, 21:19 UTC

Winsten

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:06 UTC

Winsten

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dec 2025, 21:04 UTC

Winsten

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dec 2025, 21:04 UTC

Winsten

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dec 2025, 21:03 UTC

Winsten

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer Vergelijking

Prijswijziging

Pulmatrix Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pulmatrix Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.